LOXO-101

Known as: Trk Inhibitor LOXO-101 
An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, LOXO-101 binds to Trk… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
1Memorial Sloan Kettering Cancer Center, New York, NY; 2University of Texas Southwestern, Dallas, TX; 3Stanford University School… (More)
Is this relevant?
Review
2017
Review
2017
The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2017
2017
Efforts to develop genomically targeted therapy for glioblastoma (GBM) have been unsuccessful to date. Fusions involving the… (More)
Is this relevant?
2017
2017
Neurotrophic tyrosine kinase genes encode for the Trk-family proteins TrkA, TrkB, and TrkC, which have an important role in the… (More)
Is this relevant?
2016
2016
Infantile fibrosarcoma (IFS) is a rare pediatric cancer typically presenting in the first 2 years of life. Surgical resection is… (More)
  • figure 1
Is this relevant?
2016
2016
  • 2016
LOXO-101, which targets proteins encoded by gene fusions involving NTRK1, NTRK2, and NTRK3, and entrectinib, which targets fusion… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
UNLABELLED Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related downstream signaling… (More)
Is this relevant?
2015
2015
Baseline Characteristics Pharmacokinetics (PK) of LOXO-101 During the First-in-Human Phase I Study in Patients with Advanced… (More)
Is this relevant?
2014
2014
STAMFORD, Conn., Oct. 30, 2014 (GLOBE NEWSWIRE) -Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on… (More)
Is this relevant?